A substantial entry of new drugs in the development pipeline, combined with accelerated innovation and increasing competition in the market has drawn attention to the demand for more patient-friendly dosage forms. Oral dosage forms continue to be preferred by developers due to ease of manufacturing and cost-effectiveness. From patients’ perspectives, oral dosage forms are also the preferred choice because of their familiarity and ease of self-administration. In this webinar, participants will both hear a panel of industry experts discuss practical challenges in oral drug development and gain valuable insights into current approaches to overcoming challenges in developing oral dosage forms that are more patient-friendly.
Cornell Stamoran is a life sciences industry strategist and has spent nearly 25 years engaged with the health care industry, including 20 years in advanced drug delivery. Cornell has directly participated in the development of drug design-enabled adherence and outcomes enhancement strategies for more than 150 branded drugs over the last 10 years. He holds several professional certifications and is a graduate of the University of Michigan.
Lisa Caralli is Senior Director of Scientific Advisory at Catalent overseeing small molecule support for North America. She has over 30 years of industry experience in pharmaceutical research and development, with a focus on early phase approaches to the chemistry manufacturing and control of small molecules and peptides. Lisa has held previous product development positions at Ionis Pharmaceuticals, Amylin Pharmaceuticals and the Immune Response Corporation and holds a B.S. in Biochemistry from the University of California at Davis.
Prof. Dr. Sven Stegemann is a professor of patient-centric drug design and manufacturing at the Graz University of Technology, Austria. Over the course of his 27-year career in the pharmaceutical industry, he has worked as an advisor to major pharmaceutical companies on ways to improve the design, development, and manufacture of pharmaceutical products so they better address the individual needs of patients. In his academic role, he focuses his research on the rational development of patient-centric drug products and their associated manufacturing technologies, as well as the education and training of students and young scientists.
Fabrice Ruiz is the CEO of ClinSearch, a Clinical Research Organization he co-founded in 1999. ClinSearch conducts clinical and epidemiological studies but also develops its own R&D programs for the analysis of large databases and the modeling of multidimensional concepts (acceptability, cognition…). From an academic point of view, he is president of the scientific steering committee of Institut Carnot Cognition (20 academic laboratories) and member of the board of a “Grande Ecole” (Engineering school in biotechnology). He is an active member of EuPFI (European Pediatric Formulation Initiative). Fabrice is also member of various expert groups such as Smart Health Strategic Value Chain (European Commission), Health Technology Assessment (Conect4children) and Formulation (Conect4children). He is also an active member of the R2G group from the Assistance Publique des Hôpitaux de Paris which is conducting researches on galenic and geriatric issues.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.